Lineage Cell Therapeutics, Inc. (LCTX): Total Assets
$112.58M
As of 2025-12-31
$106.22M
As of 2026-06-30
-3.1%
3-year compound annual growth
+0.8%
5-year compound annual growth
+1.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.58M | -0.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $113.22M | +12.1% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $101.02M | -18.3% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $123.66M | -29.2% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $174.54M | +61.7% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $107.95M | -14.0% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $125.48M | +23.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $101.66M | -41.3% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $173.24M | +21.5% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $142.57M | +50.6% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $94.66M | +26.4% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $74.90M | +29.7% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $57.73M | +94.1% | 2015-03-11, Balance as of period end |
| 2012-12-31 | $29.75M | -35.1% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $45.83M | -14.0% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $53.27M | n/a | 2012-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $621.33M | -28.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $343.32M | +114.1% |
Compare LCTX, RLAY, PTHS, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗